Study of the Efficacy & Safety of AMAG-423 (Digoxin Immune Fab) in

Updated 04/23/2024

Status Terminated

Clinical Trial Summary

This study evaluates the use of AMAG-423 (Digoxin Immune Fab) in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03008616
Study type	Interventional
Source	AMAG Pharmaceuticals, Inc.
Contact
Status	Terminated
Phase	Phase 2/Phase 3
Start date	April 12, 2017
Completion date	August 13, 2020

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT04725812` - Complement Regulation to Undo Systemic Harm in Preeclampsia	Phase 2
	Active, not recruiting	`NCT03744988` - Serum Androgen Levels as a Marker for the Severity of Preeclampsia
	Completed	`NCT02189148` - First-trimester Prediction of Preeclampsia
	Completed	`NCT04058405` - Risk Prediction Models for Adverse Maternal and Neonatal Outcomes in Preeclampsia
	Completed	`NCT03164304` - Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia	Phase 4
	Not yet recruiting	`NCT06265415` - Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine	N/A
	Completed	`NCT02379832` - Pre-Eclampsia And Growth Restriction: a Longitudinal Study
	Not yet recruiting	`NCT01538121` - Antiphospholipid Antibodies and Early Severe Preeclampsia.	N/A
	Recruiting	`NCT01906567` - İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels?	N/A
	Recruiting	`NCT01382732` - Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia	Phase 3
	Completed	`NCT01408979` - Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia	Phase 4
	Completed	`NCT01538147` - Restless Leg Syndrome and Severe Preeclampsia	N/A